Dopamine transporter gene, response to methylphenidate and cerebral blood flow in attention-deficit/hyperactivity disorder: A pilot study

被引：51

作者：

Rohde, LA

Roman, T

Szobot, C

Cunha, RD

Hutz, MH

Biederman, J

机构：

[1] Univ Fed Rio Grande Sul, Serv Psiquiat Infancia & Adolescencia, Hosp Clin Porto Alegre, ADHD Outpatient Clin, BR-90035003 Porto Alegre, RS, Brazil

[2] Univ Fed Rio Grande Sul, Dept Genet, BR-90035003 Porto Alegre, RS, Brazil

[3] Hosp Clin Porto Alegre, Nucl Med Serv, Porto Alegre, RS, Brazil

[4] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pediat Psychopharmacol Unit, Boston, MA USA

来源：

SYNAPSE | 2003年 / 48卷 / 02期

关键词：

ADHD; DAT1; gene; SPECT; methylphenidate;

D O I：

10.1002/syn.10186

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

The homozygosity of the 10-repeat allele at dopamine transporter gene (DAT1) seems to be associated with a poor response to methylphenidate (MPH),in children with attention-deficit/hyperactivity disorder (ADHD). This pilot study aimed to simultaneously assess polymorphisms at DAT1, response to MPH, and neuroimaging. Only ADHD children with at least a moderate response to MPH were included. Significantly higher regional cerebral blood flows assessed by single photon emission computerized tomography (SPECT) were detected in medial frontal and left basal ganglia areas in children with homozygosity for the 10-repeat allele at DAT1 gene (n = 4) than in children without this genotype (n = 4) (P < 0.05). These findings provide a preliminary connection between pharmacogenetics and neurobiological investigations on stimulant treatment of ADHD. (C) 2003 Wiley-Liss, Inc.

引用

页码：87 / 89

页数：3

共 10 条

[1]

[Anonymous], 1994, AM PSYCHIATR ASSOC

[2]

Fuke S., 2001, Pharmacogenomics Journal, V1, P152

[3] Review of neuroimaging studies of child and adolescent psychiatric disorders from the past 10 years [J].

Hendren, RL ;

De Backer, I ;

Pandina, GJ .

JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2000, 39 (07) :815-828

[4] Dopamine transporter gene and response to methylphenidate in attention-deficit/hyperactivity disorder [J].

Roman, T ;

Szobot, C ;

Martins, D ;

Biederman, J ;

Rohde, LA ;

Hutz, MH .

PHARMACOGENETICS, 2002, 12 (06) :497-499

[5] Attention-deficit hyperactivity disorder: A study of association with both the dopamine transporter gene and the dopamine D4 receptor gene [J].

Roman, T ;

Schmitz, M ;

Polanczyk, G ;

Eizirik, M ;

Rohde, LA ;

Hutz, MH .

AMERICAN JOURNAL OF MEDICAL GENETICS, 2001, 105 (05) :471-478

[6] Anti-hyperactivity medication: methylphenidate and amphetamine [J].

Seeman, P ;

Madras, BK .

MOLECULAR PSYCHIATRY, 1998, 3 (05) :386-396

[7] Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle [J].

Spencer, T ;

Biederman, J ;

Wilens, T ;

Harding, M ;

ODonnell, BAD ;

Griffin, S .

JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1996, 35 (04) :409-432

[8] Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: Therapeutic implications [J].

Volkow, ND ;

Wang, GJ ;

Fowler, JS ;

Logan, J ;

Franceschi, D ;

Maynard, L ;

Ding, YS ;

Gatley, SJ ;

Gifford, A ;

Zhu, W ;

Swanson, JM .

SYNAPSE, 2002, 43 (03) :181-187

[9]

VOLKOW ND, 2001, J NEUROSCI, V21, P1

[10] Association of the dopamine transporter gene (DAT1) with poor methylphenidate response [J].

Winsberg, BG ;

Comings, DE .

JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1999, 38 (12) :1474-1477

← 1 →